| Jason Hartig, | |
|
1717 6th Ave S, Birmingham, AL 35233-1801 | |
| (800) 822-8816 | |
| Not Available |
| Full Name | Jason Hartig |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 27 Years |
| Location | 1717 6th Ave S, Birmingham, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023038064 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 21301 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Alabama Hospital | Birmingham, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Alabama Health Services Foundation, Pc | 1951213107 | 2344 |
News Archive
Instem, a leading provider of early drug development software solutions, announced today that Mitsubishi Chemical Medience Corporation has purchased the Provantis preclinical software solution.
The National Institute of General Medical Sciences of NIH has awarded a Small Business Innovative Research grant to Allele Biotechnology and Pharmaceuticals to develop new single-domain nanoantibody therapies for the treatment of sepsis.
Neogen Corporation has developed a quick and easy new test for aflatoxin, a toxin considered by many to be the most potent, naturally-occurring carcinogen. The toxin is a by-product of mold growth in a wide range of commodities, including corn.
Geron Corporation has announced the issuance of U.S. Patent No. 7,425,448, with broad claims to cardiomyocytes derived from human embryonic stem cells (hESCs). The patent runs until at least April 2025 (subject to any patent term extension that may be available). Geron's GRNCM1 program is developing hESC-derived cardiomyocytes for the treatment of heart disease.
› Verified 7 days ago
| Entity Name | University Of Alabama Health Services Foundation, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093768723 PECOS PAC ID: 1951213107 Enrollment ID: O20031105000261 |
News Archive
Instem, a leading provider of early drug development software solutions, announced today that Mitsubishi Chemical Medience Corporation has purchased the Provantis preclinical software solution.
The National Institute of General Medical Sciences of NIH has awarded a Small Business Innovative Research grant to Allele Biotechnology and Pharmaceuticals to develop new single-domain nanoantibody therapies for the treatment of sepsis.
Neogen Corporation has developed a quick and easy new test for aflatoxin, a toxin considered by many to be the most potent, naturally-occurring carcinogen. The toxin is a by-product of mold growth in a wide range of commodities, including corn.
Geron Corporation has announced the issuance of U.S. Patent No. 7,425,448, with broad claims to cardiomyocytes derived from human embryonic stem cells (hESCs). The patent runs until at least April 2025 (subject to any patent term extension that may be available). Geron's GRNCM1 program is developing hESC-derived cardiomyocytes for the treatment of heart disease.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jason Hartig, 1717 6th Ave S, Birmingham, AL 35233-1801 Ph: () - | Jason Hartig, 1717 6th Ave S, Birmingham, AL 35233-1801 Ph: (800) 822-8816 |
News Archive
Instem, a leading provider of early drug development software solutions, announced today that Mitsubishi Chemical Medience Corporation has purchased the Provantis preclinical software solution.
The National Institute of General Medical Sciences of NIH has awarded a Small Business Innovative Research grant to Allele Biotechnology and Pharmaceuticals to develop new single-domain nanoantibody therapies for the treatment of sepsis.
Neogen Corporation has developed a quick and easy new test for aflatoxin, a toxin considered by many to be the most potent, naturally-occurring carcinogen. The toxin is a by-product of mold growth in a wide range of commodities, including corn.
Geron Corporation has announced the issuance of U.S. Patent No. 7,425,448, with broad claims to cardiomyocytes derived from human embryonic stem cells (hESCs). The patent runs until at least April 2025 (subject to any patent term extension that may be available). Geron's GRNCM1 program is developing hESC-derived cardiomyocytes for the treatment of heart disease.
› Verified 7 days ago
Robert Patrick Richter, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1600 7th Ave S, Birmingham, AL 35233 Phone: 205-638-9100 | |
Dr. Mary Orr, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1600 7th Ave S, Birmingham, AL 35233 Phone: 205-638-9100 Fax: 205-934-7273 | |
Roger Dean Bruce, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 2660 10th Ave S, Suite 636, Birmingham, AL 35205 Phone: 205-930-2220 Fax: 205-930-2223 | |
Stephanie Berger, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1600 7th Ave S, Mcwane Building Suite 108, Birmingham, AL 35233 Phone: 205-638-2904 | |
Jaime Dion Mckinney, Pediatrics Medicare: Medicare Enrolled Practice Location: 703 Volker Hl, Birmingham, AL 35294 Phone: 205-934-3795 | |
Worth Littlejohn Barbour, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 619 19th St S, Birmingham, AL 35249 Phone: 205-939-9587 | |
Timothy Todd Fleenor, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 619 19th St S, Birmingham, AL 35249 Phone: 205-934-5004 |